SCHEMBL2117568

SCHEMBL2117568

[CH2]c1ccccc1OC(C)CC

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 3/20 0.45
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.36
LMNA P02545 1/20 0.36
MTNR1A P48039 1/20 0.36
MTNR1B P49286 1/20 0.36
KDM4E B2RXH2 3/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
GABRP O00591 1/20 0.35
GABRD O14764 1/20 0.35
GABRA1 P14867 1/20 0.35
GABRB1 P18505 1/20 0.35
GABRG2 P18507 1/20 0.35
GABRB3 P28472 1/20 0.35
GABRA5 P31644 1/20 0.35
GABRA3 P34903 1/20 0.35
GABRA2 P47869 1/20 0.35
GABRB2 P47870 1/20 0.35
GABRA4 P48169 1/20 0.35
GABRE P78334 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31490284 0.85 MCHR1 (0.51) MCHR1KMT2AMEN1LMNAMTNR1A
SCHEMBL232646 0.79 IRAK4 (0.47) MCHR1KMT2AMEN1LMNAKDM4E
SCHEMBL7834704 0.78 MCHR1 (0.38) MCHR1KMT2AMEN1LMNAKDM4E
SCHEMBL10878963 0.78 HTT (0.33) MCHR1KMT2AMEN1LMNAMTNR1A
SCHEMBL18892669 0.78 MCHR1 (0.46) MCHR1KMT2AMEN1LMNAKDM4E
SCHEMBL13534463 0.78 MCHR1 (0.46) MCHR1KMT2AMEN1LMNAKDM4E
SCHEMBL9190751 0.78 MCHR1 (0.46) MCHR1KMT2AMEN1LMNAMTNR1A
SCHEMBL2120865 0.77 LMNA (0.39) KMT2ALMNAKDM4EL3MBTL1MAPT
SCHEMBL20739977 0.77 MCHR1 (0.43) MCHR1KMT2AMEN1LMNAMTNR1A
SCHEMBL23644285 0.76 MCHR1 (0.45) MCHR1KMT2AMEN1LMNAMTNR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2006103119-A2 TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND ALSO IN COSMETICS GALDERMA RESEARCH & DEVELOPMENT (FR) 2006-10-05 WO claimed
US-11718758-B2 Aqueous dispersion of colored particles MITSUBISHI PENCIL COMPANY, LIMITED (JP) 2023-08-08 US disclosed
EP-3725854-B1 COLORED PARTICLE AQUEOUS DISPERSION MITSUBISHI PENCIL CO (JP) 2023-07-05 EP disclosed
CN-111465662-B Aqueous dispersion of coloured particles 三菱铅笔株式会社 2023-05-26 CN disclosed
WO-2021241484-A1 WRITING IMPLEMENT 三菱鉛筆株式会社 2021-12-02 WO disclosed
US-20210071006-A1 AQUEOUS DISPERSION OF COLORED PARTICLES MITSUBISHI PENCIL COMPANY, LIMITED (JP) 2021-03-11 US disclosed
EP-3725854-A1 COLORED PARTICLE AQUEOUS DISPERSION MITSUBISHI PENCIL COMPANY, LIMITED (JP) 2020-10-21 EP disclosed
CN-111465662-A Aqueous dispersions of pigmented particles 三菱铅笔株式会社 2020-07-28 CN disclosed
EP-3444304-A1 POLYFUNCTIONAL POLYMERIZABLE COMPOUND AND COLORED COMPOSITION FUJIFILM Wako Pure Chemical Corporation (JP) 2019-02-20 EP disclosed
US-8802895-B2 Amide derivatives of benzene-sulfonanilide, pharmaceutical composition thereof and method for cancer treatment using the same CLEVELAND STATE UNIVERSITY (US) 2014-08-12 US disclosed
EP-2629767-A1 AMIDE DERIVATIVES OF BENZENE-SULFONANILIDE, PHARMACEUTICAL COMPOSITION THEREOF AND METHOD FOR CANCER TREATMENT USING THE SAME Cleveland State University (US) 2013-08-28 EP disclosed
WO-2012054417-A1 AMIDE DERIVATIVES OF BENZENE-SULFONANILIDE, PHARMACEUTICAL COMPOSITION THEREOF AND METHOD FOR CANCER TREATMENT USING THE SAME CLEVELAND STATE UNIVERSITY (US) 2012-04-26 WO disclosed
US-20120095092-A1 AMIDE DERIVATIVES OF BENZENE-SULFONANILIDE, PHARMACEUTICAL COMPOSITION THEREOF AND METHOD FOR CANCER TREATMENT USING THE SAME CLEVELAND STATE UNIVERSITY 2012-04-19 US disclosed
WO-2006103119-A2 TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND ALSO IN COSMETICS GALDERMA RESEARCH & DEVELOPMENT (FR) 2006-10-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095092-A1 AMIDE DERIVATIVES OF BENZENE-SULFONANILIDE, PHARMACEUTICAL COMPOSITION THEREOF AND METHOD FOR CANCER TREATMENT USING THE SAME RB1, BCR, NRAS MCHR1 3677/4885KMT2A 394/4885MEN1 3550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.